Posted by Michael Wonder on 11 Feb 2019
SMC - February 2019 decisions
11 February 2019 - A medicine used to treat a rare blood cancer in children and young adults has today been accepted by the Scottish Medicines Consortium for use in NHSScotland.
Tisagenlecleucel (Kymriah) is used to treat acute lymphoblastic leukaemia in children and young adults who have not responded to previous treatment or in whom the condition has relapsed. Tisagenlecleucel was accepted following consideration through the SMC’s Patient and Clinician Engagement process, which is used for medicines to treat end of life and very rare conditions.
Dabrafenib (Tafinlar) was accepted for use in combination with another medicine, trametinib, for the treatment of stage III melanoma (skin cancer) in patients following surgical removal of the tumour.
Tofacitinib citrate (Xeljanz) was accepted for the treatment of moderately to severely active ulcerative colitis, a disease which causes inflammation of the gut.
